Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data

Retinal Diseases

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Br J Ophthalmol

Nguyen CT, Lassen RKB, Mæng MO, Lee C, Subhi Y, Vorum H, Wykoff CC, Ørskov M, Cehofski LJ

doi: 10.1136/bjo-2025-329273

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

LensesMacular Diseases

Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings

BMC Ophthalmol

Hengerer FH, Stanzel B, Hoyos-Chacon J, Suarez M, Beckers S, Busatto P, Badalà F

doi: 10.1186/s12886-025-04515-9

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular DiseasesRetinal Diseases

Malabsorption Syndromes and Risk of Age-Related Macular Degeneration: Evidence from Real-World Data

Ophthalmol Retina

Jeong H, Eppel PS, Kaelber DC, Singh RP, Talcott KE

doi: 10.1016/j.oret.2026.01.002

Macular DiseasesRetinal Diseases

Neovascular Age-Related Macular Degeneration Treated with Aflibercept: Five-Year Follow-Up and Correlation with Optical Coherence Tomography Biomarkers in a Real-World Setting

Ophthalmol Ther

Borselli M, Elfalah M, Trunfio TA, Scala A, Chisari D, Mancini A, Lucisano A, Carnovale-Scalzo G, Mollace V, Improta G, Zweifel S, Scorcia V, Toro MD, Carnevali A

doi: 10.1007/s40123-025-01232-w

Macular Diseases

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Retina

Lee C, Karunainathan MG, Zohalinejad KD, Mæng MO, Fabrin NW, Yde SK, Wykoff CC, Abildgaard SK, Vorum H, Subhi Y, Ørskov M, Cehofski LJ

doi: 10.1097/IAE.0000000000004888

Macular Diseases

Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials

Br J Ophthalmol

Zhang C, Sonik NR, Ayoubi M, AbouKasm G, Zhu D, Fan JC, Albini TA, Yannuzzi NA

doi: 10.1136/bjo-2025-328196

Macular Diseases

Real-World Case Series of Intravitreal Pegcetacoplan for Geographic Atrophy Secondary to Age-related Macular Degeneration in Switzerland

Klin Monbl Augenheilkd

Gabathuler F, Cozzi M, Fasler K, Maloca PM, Blaser F, Zweifel S

doi: 10.1055/a-2825-0926

Related content

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Malabsorption Syndromes and Risk of Age-Related Macular Degeneration: Evidence from Real-World Data

Neovascular Age-Related Macular Degeneration Treated with Aflibercept: Five-Year Follow-Up and Correlation with Optical Coherence Tomography Biomarkers in a Real-World Setting

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials

Real-World Case Series of Intravitreal Pegcetacoplan for Geographic Atrophy Secondary to Age-related Macular Degeneration in Switzerland